According to FutureWise analysis the market for fragment-based drug discovery in 2025 is US$ 1.05 billion, and is expected to reach US$ 2.47 billion by 2033 at a CAGR of 11.29%. The pharmaceutical industry is experiencing growth driven by the demand for efficient and cost-effective drug development, especially for complex targets. The adoption of advanced biophysical screening, AI-driven molecular modeling, and strong R&D investments are enhancing fragment-based drug discovery (FBDD) methods. As more therapies from FBDD pipelines gain regulatory approvals, the market gains momentum in oncology, immunology, and infectious disease therapeutics.
Fragment-based drug discovery (FBDD) represents a sophisticated and growing approach in contemporary drug development, centering on the identification of small chemical fragments as initial candidates for creating highly effective therapeutic compounds. Unlike traditional high-throughput screening (HTS), which evaluates extensive libraries of complex molecules, FBDD focuses on smaller libraries of low-molecular-weight fragments that exhibit weak but efficient binding to biological targets. These fragments generally feature simple structural components and contain fewer atoms, which allows them to explore a wider chemical space with fewer compounds.
In the FBDD process, these fragments are screened against biological targets using precise biophysical techniques such as nuclear magnetic resonance (NMR), X-ray crystallography, surface plasmon resonance (SPR), and thermal shift assays. After identifying potential fragment hits, medicinal chemists optimize these fragments iteratively through strategies including fragment growing, linking, or merging, ultimately developing full-sized drug candidates that demonstrate significantly enhanced potency, selectivity, and pharmacokinetic properties.
A significant advantage of FBDD is its capability to uncover novel binding sites that may not be detectable through conventional screening methods. This is particularly beneficial for challenging targets, such as protein–protein interactions and enzymes with shallow binding pockets. The inherent simplicity of fragments also minimizes the risk of creating compounds with poor drug-like properties, facilitating a more efficient and rational lead optimization process.
FBDD has already led to the discovery of various successful approved drugs and candidates currently in clinical development, especially in the fields of oncology, inflammation, and infectious diseases. Notable examples include Vemurafenib for melanoma, Venetoclax for leukemia, and Erdafitinib for bladder cancer, all of which stem from fragment-based strategies.
As advancements in structural biology, AI-driven modeling, and computational chemistry continue, the role of fragment-based drug discovery is anticipated to grow—accelerating drug discovery timelines, reducing costs, and enabling the development of next-generation therapeutics targeting complex and previously undruggable conditions.

FutureWise Market Research has published a report that provides an insightful analysis of Fragment-based Drug Discovery Market trends that are affecting the overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=9258&type=requestsample
Fragment-based Drug Discovery Market Segmentation:
By Services Component
• Fragment Screening
o Biophysical Techniques
 Nuclear Magnetic Resonance (NMR) Spectroscopy
 Differential scanning Fluorimetry (DSF) Assay (Thermal Shift)
 Fluorescence Polarization (FP)
 Isothermal Titration Calorimetry (ITC)
 X-ray Crystallography
 Surface Plasmon Resonance
 Biolayer Interferometry
 Mass Spectrometry
 Capillary Electrophoresis
 Others (Biochemical Assays)
o Non-biophysical Techniques
• Fragment Optimization

By End-User
• Biopharmaceutical Companies
• CROs
• Academic and Research Institutions

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Fragment-based Drug Discovery Market:
• Astex Pharmaceuticals
• Beactica AB
• Structure Based Design, Inc.
• Alveus Pharmaceuticals Pvt. Ltd.
• Emerald BioStructures, Inc.
• Evotec AG,
• Crown Bioscience, Inc.
• Kinetic Discovery Limited
• Sprint Bioscience
• Proteros Fragments GmbH
• Charles River Laboratories International, Inc.
• Sygnature Discovery

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=9258&license=multi


**Objectives of this Study: **
1. To provide a comprehensive analysis of the Fragment-based Drug Discovery Market By Services Component, By End-User and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: [email protected]

FutureWise Research
Contact Person: Vinay Thaploo.
Email: [email protected]
Contact Number: Asia: +91 8605575209 | UK: +44 0113 519 7222
Website: www.futurewiseresearch.com